11. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. Issue 7 (July 2017) Authors: Sandborn, William J.; Wolf, Douglas C.; Kosutic, Gordana; Parker, Gerry; Schreiber, Stefan; Lee, Scott D.; Abraham, Bincy; Afzali, Anita; Arsenescu, Razvan I.; Gutierrez, Alexandra; Spearman, Marshall; Coarse, Jason; Feagan, Brian G. Journal: Inflammatory bowel diseases Issue: Volume 23:Issue 7(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Incidence of Benign and Malignant Neoplasms in Crohn's Disease Patients Aged ≤30 Years Versus 30‐64 Years Treated With Certolizumab Pegol: Results From a Pooled Safety Analysis of 15 Studies: 1831. (October 2015) Authors: Choi, Jennifer; Ha, Christina; Kosutic, Gordana; Spearman, Marshall; Coarse, Jason; Hasan, Iram; Loftus, Edward V. Journal: American journal of gastroenterology Issue: Volume 110(2015)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Long‐Term Safety and Efficacy of Certolizumab Pegol Therapy in Patients With Moderate to Severe Crohn's Disease: 5‐Year Results: 1821. (October 2015) Authors: Ptak, Theadore; Younes, Ziad; Shafran, Ira; Lee, Scott; Miner, Philip B.; Kayhan, Cem; Kosutic, Gordana; Coarse, Jason; Hasan, Iram; Spearman, Marshall; Sandborn, William J. Journal: American journal of gastroenterology Issue: Volume 110(2015)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. OA36 Bimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study. (23rd April 2022) Authors: Tillett, William; McInnes, Iain B; McGonagle, Dennis; Jadon, Deepak R; Ink, Barbara; Assudani, Deepak; Coarse, Jason; Eells, Jason; Coates, Laura C Journal: Rheumatology Issue: Volume 61(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY. (June 2019) Authors: Heijde, Désirée van der; Gensler, Lianne S.; Deodhar, Atul; Baraliakos, Xenofon; Poddubnyy, Denis; Farmer, Mary Katherine; Baeten, Dominique; Coarse, Jason; Oortgiesen, Marga; Dougados, Maxime Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. P-098 Serious Infections in Patients Treated with Certolizumab Pegol with or Without Corticosteroids: Pooled Safety Data from 15 Clinical Trials. (March 2016) Authors: Abraham, Bincy; Wolf, Doug; Regueiro, Miguel; Randall, Charles; Kosutic, Gordana; Spearman, Marshall; Coarse, Jason; Hasan, Iram; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. P-098 Serious Infections in Patients Treated with Certolizumab Pegol with or Without Corticosteroids: Pooled Safety Data from 15 Clinical Trials. (March 2016) Authors: Abraham, Bincy; Wolf, Doug; Regueiro, Miguel; Randall, Charles; Kosutic, Gordana; Spearman, Marshall; Coarse, Jason; Hasan, Iram; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. P-099 Sex-Based Differences in Adverse Events of Crohn's Disease Patients Treated with Certolizumab Pegol: A Pooled Safety Analysis of 15 Studies. (March 2016) Authors: Kane, Sunanda; Loftus, Edward; Choudhary, Cuckoo; Randall, Charles; Ali, Tauseef; Kosutic, Gordana; Hasan, Iram; Coarse, Jason; Spearman, Marshall; Regueiro, Miguel Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. P-099 Sex-Based Differences in Adverse Events of Crohn's Disease Patients Treated with Certolizumab Pegol: A Pooled Safety Analysis of 15 Studies. (March 2016) Authors: Kane, Sunanda; Loftus, Edward; Choudhary, Cuckoo; Randall, Charles; Ali, Tauseef; Kosutic, Gordana; Hasan, Iram; Coarse, Jason; Spearman, Marshall; Regueiro, Miguel Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. P-100 Improvement in Quality of Life as a Predictor of Long-Term Remission in Crohn's Disease Patients Treated with Certolizumab Pegol. (March 2016) Authors: Feagan, Brian; Schreiber, Stefan; Spearman, Marshall; Kosutic, Gordana; Hasan, Iram; Coarse, Jason; Sandborn, William Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗